Search research articles
Contact Us
Filters
Showing results (91-100 of 97) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 97 results.
Nature Medicine
|
June 6, 2022
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
Lacey J Padrón, Deena M Maurer, Mark H O'Hara, et al.
The Journal of Experimental Medicine
|
August 27, 2024
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
Apostolia M Tsimberidou, Farah A Alayli, Kwame Okrah, et al.
Cancer Discovery
|
December 29, 2020
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis
Jun Li, Mercedes A Duran, Ninjit Dhanota, et al.
Science Translational Medicine
|
July 26, 2023
Tissue-specific features of the T cell repertoire after allogeneic hematopoietic cell transplantation in human and mouse
Susan DeWolf, Yuval Elhanati, Katherine Nichols, et al.
Cancer Immunology Research
|
June 12, 2025
Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor That Unleashes PD-1 Checkpoint and CAR T-Cell Immunotherapies
Michael Wichroski, Si-Qi Liu, Lauren M Zasadil, et al.
Nature
|
December 14, 2022
Ovarian cancer mutational processes drive site-specific immune evasion
Ignacio Vázquez-García, Florian Uhlitz, Nicholas Ceglia, et al.
Journal for Immunotherapy of Cancer
|
December 21, 2025
Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI)
Sam Sater, Carlo B Bifulco, Jaime Rodriguez-Canales, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 97) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 97 results.
Nature Medicine
|
June 6, 2022
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
Lacey J Padrón, Deena M Maurer, Mark H O'Hara, et al.
The Journal of Experimental Medicine
|
August 27, 2024
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
Apostolia M Tsimberidou, Farah A Alayli, Kwame Okrah, et al.
Cancer Discovery
|
December 29, 2020
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis
Jun Li, Mercedes A Duran, Ninjit Dhanota, et al.
Science Translational Medicine
|
July 26, 2023
Tissue-specific features of the T cell repertoire after allogeneic hematopoietic cell transplantation in human and mouse
Susan DeWolf, Yuval Elhanati, Katherine Nichols, et al.
Cancer Immunology Research
|
June 12, 2025
Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor That Unleashes PD-1 Checkpoint and CAR T-Cell Immunotherapies
Michael Wichroski, Si-Qi Liu, Lauren M Zasadil, et al.
Nature
|
December 14, 2022
Ovarian cancer mutational processes drive site-specific immune evasion
Ignacio Vázquez-García, Florian Uhlitz, Nicholas Ceglia, et al.
Journal for Immunotherapy of Cancer
|
December 21, 2025
Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI)
Sam Sater, Carlo B Bifulco, Jaime Rodriguez-Canales, et al.
Page
of 10